The Experts below are selected from a list of 35541 Experts worldwide ranked by ideXlab platform
Ludwig Deml - One of the best experts on this subject based on the ideXlab platform.
-
Long-term HBsAg-expression by human primary hepatocytes following infection with recombinant vaccinia viruses.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:Human primary liver cells were isolated by EGTA/collagenase-perfusion and cultivated between 2 collagen layers. After infection with HBsAg-recombinant vaccinia viruses, the HBsAg concentration was determined from the supernatant over a period of more than 40 days using an IMx MEIA test.
-
Expression of HBsAg particles by recombinant vaccinia viruses in different cell lines.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:(A) The hepatoma cell line HuH-7 was infected with various M.O.I. [multiplicity of infection] of HBsAg-recombinant vaccinia viruses. The expression level of HBsAg was measured from the cell culture supernatant (S/N-value) by an IMx microparticle enzyme immunoassay at indicated time points: 24, 48, 72, and 96 h after infection. (B) HuH-7 hepatoma cells, primary hepatocytes, and HepG2 were comparatively infected with recombinant vaccinia viruses at the indicated M.O.I´s. Four days after infection, cells were harvested, and the expression level of HBsAg was measured in the supernatant by an IMx microparticle enzyme immunoassay.
-
Electron microscopy of microparticle-purified HBsAg particles derived from recombinant vaccinia virus-infected primary hepatocytes.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:HBsAg particles (22 nm) were negatively stained with 2% aqueous phosphotungstic acid (pH 7.3) and examined by electron microscopy.
Edith Reuschel - One of the best experts on this subject based on the ideXlab platform.
-
Long-term HBsAg-expression by human primary hepatocytes following infection with recombinant vaccinia viruses.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:Human primary liver cells were isolated by EGTA/collagenase-perfusion and cultivated between 2 collagen layers. After infection with HBsAg-recombinant vaccinia viruses, the HBsAg concentration was determined from the supernatant over a period of more than 40 days using an IMx MEIA test.
-
Expression of HBsAg particles by recombinant vaccinia viruses in different cell lines.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:(A) The hepatoma cell line HuH-7 was infected with various M.O.I. [multiplicity of infection] of HBsAg-recombinant vaccinia viruses. The expression level of HBsAg was measured from the cell culture supernatant (S/N-value) by an IMx microparticle enzyme immunoassay at indicated time points: 24, 48, 72, and 96 h after infection. (B) HuH-7 hepatoma cells, primary hepatocytes, and HepG2 were comparatively infected with recombinant vaccinia viruses at the indicated M.O.I´s. Four days after infection, cells were harvested, and the expression level of HBsAg was measured in the supernatant by an IMx microparticle enzyme immunoassay.
-
Electron microscopy of microparticle-purified HBsAg particles derived from recombinant vaccinia virus-infected primary hepatocytes.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:HBsAg particles (22 nm) were negatively stained with 2% aqueous phosphotungstic acid (pH 7.3) and examined by electron microscopy.
Geretti, Anna Maria - One of the best experts on this subject based on the ideXlab platform.
-
The global prevalence of hepatitis D virus infection:systematic review and metaanalysis
'Elsevier BV', 2020Co-Authors: Stockdale, Alexande J, Kreuels Enno, Giorgi Emanuele, Kyomuhangi Irene, De Martel Catherine, Huti Yva, Henrion, Marc R. Y., Geretti, Anna MariaAbstract:Background and Aims There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people. Methods We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models. Results We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC. Conclusions An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates
-
The global prevalence of hepatitis D virus infection: systematic review and meta-analysis
'Elsevier BV', 2020Co-Authors: Stockdale, Alexande J, Kreuels Enno, Henrion, Marc Y, Giorgi Emanuele, Kyomuhangi Irene, De Martel Catherine, Huti Yva, Geretti, Anna MariaAbstract:Background and Aims There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people. Methods We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models. Results We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC. Conclusions An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates
Antoine Chére - One of the best experts on this subject based on the ideXlab platform.
-
Bayesian predictors of HBsAg clearance on HIV/HBV therapy.
2019Co-Authors: Pierre Gantne, Laure Cotte, Clotilde Allavena, Firouzé Ani-sad, Thomas Huleu, Claudine Duvivie, Marc-antoine Valanti, Christine Jacome, Véronique Joly, Antoine ChéreAbstract:Bayesian predictors of HBsAg clearance on HIV/HBV therapy.
-
Study flowchart.
2019Co-Authors: Pierre Gantne, Laure Cotte, Clotilde Allavena, Firouzé Ani-sad, Thomas Huleu, Claudine Duvivie, Marc-antoine Valanti, Christine Jacome, Véronique Joly, Antoine ChéreAbstract:Of 59829 HIV-infected individuals enrolled in the Dat’AIDS cohort between 2006 and 2016, 1419 harbored HBsAg for at least 6 months and subsequently initiated cART-anti-HBV treatment. Individuals received one of the following HBV therapy schedule: (1) 3TC or FTC only (n = 150), (2) TDF with or without 3TC or FTC (n = 489); and (3) 3TC or FTC as first line followed by adding/switching to TDF as second line with or without 3TC or FTC (n = 780). TDF, Tenofovir disoproxil fumarate; 3TC, lamivudine; FTC, emtricitabine.
Irgi Seelbach-goebel - One of the best experts on this subject based on the ideXlab platform.
-
Long-term HBsAg-expression by human primary hepatocytes following infection with recombinant vaccinia viruses.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:Human primary liver cells were isolated by EGTA/collagenase-perfusion and cultivated between 2 collagen layers. After infection with HBsAg-recombinant vaccinia viruses, the HBsAg concentration was determined from the supernatant over a period of more than 40 days using an IMx MEIA test.
-
Expression of HBsAg particles by recombinant vaccinia viruses in different cell lines.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:(A) The hepatoma cell line HuH-7 was infected with various M.O.I. [multiplicity of infection] of HBsAg-recombinant vaccinia viruses. The expression level of HBsAg was measured from the cell culture supernatant (S/N-value) by an IMx microparticle enzyme immunoassay at indicated time points: 24, 48, 72, and 96 h after infection. (B) HuH-7 hepatoma cells, primary hepatocytes, and HepG2 were comparatively infected with recombinant vaccinia viruses at the indicated M.O.I´s. Four days after infection, cells were harvested, and the expression level of HBsAg was measured in the supernatant by an IMx microparticle enzyme immunoassay.
-
Electron microscopy of microparticle-purified HBsAg particles derived from recombinant vaccinia virus-infected primary hepatocytes.
2019Co-Authors: Edith Reuschel, Wolfgang Jilg, Irgi Seelbach-goebel, Ludwig DemlAbstract:HBsAg particles (22 nm) were negatively stained with 2% aqueous phosphotungstic acid (pH 7.3) and examined by electron microscopy.
